Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Female aged ≥ 18 years.~2. Patients with histologic or cytologic diagnosis of breast cancer with evidence of metastatic disease with documented HER-2 negative status and eligible for treatment with paclitaxel.~3. Patients with at least one baseline measurable lesion according to RECIST version 1.1 criteria.~4. Zubrod (Eastern Co-operative Oncology Group \[ECOG\]) Performance Status (PS) of 0-1.~5. An electrocardiogram (ECG) with no clinically significant abnormalities indicative of myocardial ischemia.~6. Ongoing toxicity associated with prior anticancer therapy ≤ grade 1 Common Terminology Criteria for Adverse Events (CTCAE version 4.03) with the exception of alopecia.~7. Maximum of three prior chemotherapy lines for advanced breast cancer (not including neo/adjuvant chemotherapy). If prior treatment with paclitaxel, PD must have occurred \> 12 months from the end of previous adjuvant treatment or for previous metastatic treatment no PD must have occurred during treatment or within 3 months of the end of treatment~8. Life expectancy of at least three months.~9. Patients must be able to swallow and retain oral medication (intact tablet).~10. Able to undergo all screening assessments outlined in the protocol following written informed consent.~11. Adequate organ function (defined by the following parameters):~    1. Serum creatinine \< 140 µmol/L or creatinine clearance \> 60 mL/min.~   2. Serum hemoglobin ≥ 9 g/dL; absolute neutrophil count ≥ 1.5 x 10\*\*9/L; platelets ≥ 100 x 10\*\*9/L.~   3. Serum bilirubin ≤ 1.5 x upper normal limit (UNL).~   4. Serum ALT, AST ≤ 2.5 x UNL but ≤ 5.0 x UNL in case of liver metastases; ALP ≤ UNL but ≤ 1.5 x ULN in case of liver metastases; albumin within normal limits. If ALP is greater than 1.5 x UNL (in the presence of liver metastases) the liver isoenzyme fraction will be measured. Liver isoenzyme fraction (absolute value) must be ≤ 1.5 x UNL.~12. No known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus Ι and -ΙΙ positive status.~Exclusion Criteria:~1. Male.~2. Pregnancy or lactation or unwillingness to use adequate method of birth control.~3. HER-2 positive disease status.~4. Less than four weeks since last chemotherapy, radiotherapy or prior investigational therapy. Less than two weeks since last hormone or immunotherapy or signal transduction therapy.~5. Neurological or psychiatric disorders which may influence understanding of study and informed consent procedures.~6. Active or uncontrolled infection.~7. Malabsorption syndrome, disease significantly affecting gastrointestinal function.~8. Hypersensitivity to:~   1. paclitaxel~  2. ibuprofen or to more than one non-steroidal anti-inflammatory drug.~  3. medications belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib.~9. Presence of brain metastases (this does not include primary brain tumors) or leptomeningeal disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 400 mg three times daily (t.i.d.) three weeks on one week off (three to six patients)
- Group 2 (Type: EXPERIMENTAL): Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 100% increase to 800 mg t.i.d. if no toxicity in previous group (400 mg) three weeks on one week off (three to six patients)
- Group 3 (Type: EXPERIMENTAL): Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 50% increase to 1200 mg t.i.d. if no toxicity in previous group (800 mg) three weeks on one week off (three to six patients).

Based on this trial design, predict the completion outcome and termination type (if applicable).